{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-019074","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.406327+00:00","generated_at":"2026-06-01T06:46:05.971160+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia","bullets":["KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).","ESS decreased ~9 points after 5 weeks; at week 7: ESS -9.4 (QD), -8.8 (BID); IHSS -16.1 QD, -12.3 BID.","Sleep Inertia VAS decreased 25.9 (QD) and 17.2 (BID); Brain Fog Scale decreased 23.8 (QD) and 22.3 (BID).","PK data supports nighttime dosing; European Commission granted Orphan Drug Designation for KP1077 in IH."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-019074","json":"https://secwatch.observer/filing/0001437749-24-019074.json","markdown":"https://secwatch.observer/filing/0001437749-24-019074.md","text":"https://secwatch.observer/filing/0001437749-24-019074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924019074/0001437749-24-019074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924019074/zvra20240530c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:46:05.971160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}